Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis

Haematologica

Volumn 96, Issue 12, 2011, Pages 1815-1821

  Volejnikova, Jana ^a,b   Mejstrikova, Ester ^a,b   Valova, Tatana ^a,b   Reznickova, Leona ^a,b   Hodonska, Ladislava ^a,b   Mihal, Vladimir ^c   Sterba, Jaroslav ^d   Jabali, Yahia ^e   Prochazkova, Daniela ^f   Blazek, Bohumir ^g   Hak, Jiri ^h   Cerna, Zdenka ⁱ   Hrusak, Ondrej ^a,b   Stary, Jan ^a,b   Trka, Jan ^a,b   Fronkova, Eva ^a,b  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c PALACKÝ UNIVERSITY   (Czech Republic)

^d UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^e Regional Hospital Ceske Budejovice   (Czech Republic)

^f Department of Pediatrics   (Czech Republic)

^g UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^h UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Acute lymphoblastic leukemia; Childhood; Day 15; Minimal residual disease; Peripheral blood

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLOOD EXAMINATION; BONE MARROW EXAMINATION; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HEPATOMEGALY; HUMAN; HUMAN TISSUE; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; PRE B LYMPHOCYTE; PREDICTION; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SPLENOMEGALY;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; MALE; NEOPLASM, RESIDUAL; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; TIME FACTORS;

EID: 82855168105     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.042937     Document Type: Article

References (37)

1. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. N Engl J Med. 1998;339(9):591-8.
2. Coustan Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96(8):2691-6.
3. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352 (9142):1731-8.
4. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grumayer R, van der Velden V, Fischer S, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22(4):771-82.
5. Pui CH, Relling MV, Sandlund JT, Downing JR, Campana D, Evans WE. Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol. 2004;83 (Suppl 1):S124-6.
6. Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood. 2007;109(3):926-35.
7. Zhou J, Goldwasser MA, Li A, Dahlberg SE, Neuberg D, Wang H, et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood. 2007; 110(5):1607-11.
8. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206-14.
9. Brisco MJ, Sykes PJ, Hughes E, Dolman G, Neoh SH, Peng LM, et al. Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukaemia. Br J Haematol. 1997;99(2):314-9.
10. Coustan-Smith E, Sancho J, Hancock ML, Razzouk BI, Ribeiro RC, Rivera GK, et al. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood. 2002;100(7):2399-402.
11. Martin H, Atta J, Bruecher J, Elsner S, Schardt C, Stadler M, et al. In patients with BCR-ABL-positive ALL in CR peripheral blood contains less residual disease than bone marrow: implications for autologous BMT. Ann Hematol. 1994;68(2):85-7.
12. van der Velden VH, Jacobs DC, Wijkhuijs AJ, Comans-Bitter WM, Willemse MJ, Hahlen K, et al. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia. 2002;16(8): 1432-6.
13. van Rhee F, Marks DI, Lin F, Szydlo RM, Hochhaus A, Treleaven J, et al. Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow. Leukemia. 1995;9(2):329-35.
14. Brisco MJ, Sykes PJ, Hughes E, Story CJ, Rice MS, Schwarer AP, et al. Molecular relapse can be detected in blood in a sensitive and timely fashion in B-lineage acute lymphoblastic leukemia. Leukemia. 2001; 15(11):1801-2.
15. Fronkova E, Mejstrikova E, Avigad S, Chik KW, Castillo L, Manor S, et al. Minimal residual disease (MRD) analysis in the non- MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Leukemia. 2008;22(5):989-97.
16. Mejstrikova E, Kalina T, Trka J, Stary J, Hrusak O. Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy. Leukemia. 2005;19(6):1092-4.
17. Hiddemann W, Wormann B, Ritter J, Thiel E, Gohde W, Lahme B, et al. Frequency and clinical significance of DNA aneuploidy in acute leukemia. Ann NY Acad Sci. 1986; 468:227-40.
18. Hrusak O, Trka J, Zuna J, Houskova J, Bartunkova J, Stary J. Aberrant expression of KOR-SA3544 antigen in childhood acute lymphoblastic leukemia predicts TELAML1 negativity. The Pediatric Hematology Working Group in the Czech Republic. Leukemia. 1998;12(7):1064-70.
19. Pongers-Willemse MJ, Seriu T, Stolz F, d'Aniello E, Gameiro P, Pisa P, et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia. 1999; 13(1):110-8.
20. Szczepanski T, Pongers Willemse MJ, Langerak AW, Harts WA, Wijkhuijs AJ, van Wering ER, et al. Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage. Blood. 1999;93(12):4079-85.
21. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17(12):2257-317.
22. Langerak AW, Wolvers-Tettero IL, van Gastel-Mol EJ, Oud ME, van Dongen JJ. Basic helix-loop-helix proteins E2A and HEB induce immature T-cell receptor rearrangements in nonlymphoid cells. Blood. 2001;98(8):2456-65.
23. van der Velden VH, Wijkhuijs JM, Jacobs DC, van Wering ER, van Dongen JJ. T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. Leukemia. 2002;16(7):1372-80.
24. van der Velden VH, Willemse MJ, van der Schoot CE, Hahlen K, van Wering ER, van Dongen JJ. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia. 2002;16(5):928-36.
25. Verhagen OJ, Willemse MJ, Breunis WB, Wijkhuijs AJ, Jacobs DC, Joosten SA, et al. Application of germline IGH probes in realtime quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia. 2000;14(8): 1426-35.
26. Fronkova E, Madzo J, Zuna J, Reznickova L, Muzikova K, Hrusak O, et al. TEL/AML 1 real-time quantitative reverse transcriptase PCR can complement minimal residual disease assessment in childhood ALL. Leukemia. 2005;19(7):1296-7.
27. van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of realtime quantitative PCR data. Leukemia. 2007;21(4):604-11.
28. Panzer Grumayer ER, Schneider M, Panzer S, Fasching K, Gadner H. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood. 2000;95(3):790-4.
29. Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, et al. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia. Br J Haematol. 2009;146(3):292-9.
30. Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol. 2009;27(31):5168-74.
31. Mejstrikova E, Fronkova E, Kalina T, Omelka M, Batinic D, Dubravcic K, et al. Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry. Pediatr Blood Cancer. 2010;54(1):62-70.
32. Ratei R, Basso G, Dworzak M, Gaipa G, Veltroni M, Rhein P, et al. Monitoring treatment response of childhood precursor Bcell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction. Leukemia. 2009;23(3):528-34.
33. Ojala AE, Lanning FP, Lanning BM. Abdominal ultrasound findings during and after treatment of childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1997;29(4):266-71.
34. Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994; 84(9):3122-33.
35. Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338(23):1663-71.
36. Schrappe M. Evolution of BFM trials for childhood ALL. Ann Hematol. 2004;83 (Suppl 1):S121-3.
37. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008;111(12):5477-85.